• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Cathejell with Lidocaine
    / Lapidot

    Active Ingredient *

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    25 X 12.5 g (10 g are instilled into the urethra)

    not in the basket chart 72436 3887


    Cathejell with Lidocaine is instilled into the urethra prior to the insertion of
    instruments and/or applicated onto the instrument.
    The content of one syringe is sufficient to fill the urethra.
    Never instil more than one syringe.
    The tubes contain 12,5 g, of which 10 g are instilled into the urethra.
    Slow instillation of the gel into the urethra prior to the insertion of instruments (by a physician or trained medical qualified personnel).
    1. Clean and disinfect the external orifice of the urethra.
    2. Peel off the paper from the blister back cover (possibly up to the waist of the
    transparent blister material).
    3. Break off the applicator tip (in the blister pack if required).
    Take care to remove the tip completely to prevent insertion into the urethra.
    4. Release one drop of gel for easier insertion of the applicator.
    5. Complete extrusion by applying slight steady pressure to the accordion
    The duration of application is not limited.


    Instillation into the urethra prior to the instillation of catheters or other instruments and manipulations which require the use of a local anesthetic.


    Hypersensitivity to any of the components, patients with marked bradycardial rhythm disorders.
    Do not press into the urethra after a failed catheterisation (possibly apply the gel to the instrument or aspirate urine suprapubically).
    Cathejell with Lidocaine should be used with caution in patients with severe cardiac insufficiency, seriously impaired hepatic and renal function, traumatized mucosa and/or inflammation/sepsis in the region of the proposed application and in patients with tendency to convulsions (epilepsy, severe shocks).

    Special Precautions

    Under anesthesia a lubricant without lidocaine should be used.
    Instillation should only be performed by a physician or by qualified medical
    Patients with glucose-6-phosphate dehydrogenase deficiency or congential or idiopathic methaemoglobinaemia are more susceptible to drug induced methaemoglobinaemia. Do not use in children under one year of age who are
    receiving methaemoglobinaemia inducing drugs.
    Do not use in premature infants who were born before 37 weeks of gestation.

    Side Effects

    Allergic reactions to lidocaine and chlorhexidine are extremely rare.
    In the case of hypersensitivity skin reactions are possible.
    Systemic adverse reactions to lidocaine are rare and may result from hypersensitivity or diminished tolerance.
    From the technique and duration of the application and from the lidocaine
    concentration systemic adverse reactions generally are not expected.
    Application of more than one tube whereas jelly enters into the bladder or severe inflammation of the urethra resulting in an increase of lidocaine absorption may lead to an overdose with systemic central nervous and cardiovascular reactions.
    Central nervous system reactions are excitatory and/or depressant and may be
    manifested by prodomal symptoms such as nervousness, dizziness, vertigo,
    somnolence, tremor.
    Cardiovascular reactions, characterized by bradycardia, myocardial depression and increase of ventricular activation time usually only occur at very high blood
    concentrations of lidocaine.

    Drug interactions

    Lidocaine should be used with caution in patients receiving antiarrhythmic drugs, ßreceptor blocking agents or calcium channel antagonists because of the possible additive inhibition on the cardiac P-Q transition, intraventricular excitation conducting and contractility.

    Pregnancy and Lactation

    Pregnancy: Cathejell with Lidocaine can be used during pregnancy and lactation, the risk/benefit assessment should be decided by the physician.
    Lactation: Lidocaine passes the placenta and enters breast milk in small quantities; however, there is generally no risk to the foetus and infants at the therapeutic dose level used in Cathejell with Lidocaine.


    Symptoms: Symptoms of an intoxication with lidocaine (blood concentration: >5 μg/ml) are characterized by beginning prodomal symptoms such as nervousness, dizziness, vertigo, somnolence and in more serious cases loss of consciousness, respiratory depression and cardiac arrest. More symptoms are: visual disorders, tinnitus, vomiting.
    Therapy of an intoxication: In common with other anaesthetic/antiseptic gels, treatment of a patient with systemic toxicity consists of ensuring adequate ventilation with oxygen, if necessary by assisted or controlled ventilation. If convulsions do occur, they could be treated rapidly by intravenous injections of Diazepam 5 to 15 mg.
    Necessity of circulation assisting manipulations depends on the clinical symptoms. If bradycardia or cardiac arrest occurs atropin or sympathomimetica (adrenalin) should be given intravenously as soon as possible and cardiovascular resuscitation performed.

    Optima Pharmazeutische GmbH